A new convergent route to 1-substituted ellipticines
摘要:
1-(2-Fluoro-4-pyridyl)ethanone was synthesized from 2-fluoropyridine and was ortho-lithiated after activation as the propylene glycol ketal. The resulting 3-lithio derivative was trapped by various electrophiles but reacted in low yield with N-protected 3-indolecarbaldehyde. Model compounds 1-[[[2-(diethylamino)ethyl]amino]-3-pyridyl]ethanol and -ethanone were prepared and selectively condensed with indole. 1-[[[2-(Diethylamino)-ethyl]amino]-3-pyridyl]ethanol and -ethanone bearing a ketal-protected acetyl moiety at the C-4 position have been obtained in high yields starting from the propylene glycol ketal of 1-(2-fluoro-4-pyridyl)ethanone. These reagents could not be condensed with indole either due to side reactions between the C-3 and C-4 functions or to steric hindrance. 1-(2-Substituted-4-bromo-3-pyridyl)ethanols were synthesized via a metalation/halogen-dance strategy starting from 2-fluoropyridine. 1-(2,4-Dihalo-3-pyridyl)-1-chloroethane could be prepared and condensed with 1-indolylmagnesium iodide, which allowed the construction of the expected 3-[1-(3-pyridyl)ethyl]indole skeleton. Functionalization of the pyridine C-4 bromo position was achieved by a vinylstannane cross-coupling reaction using a palladium(0) catalyst. Acidic treatment of the resulting 4-(1-ethoxyethenyl)pyridine led to 1-fluoroellipticine. The whole sequence requires six steps from indole and 2-fluoropyridine and allows an attractive overall yield.
Metallation regioselective en serie pyridinique: Synthese originale d'amino-2 aroyl-3 pyridines
作者:Timur Güngör、Francis Marsais、Guy Queguiner
DOI:10.1016/s0022-328x(00)80124-2
日期:1981.7
CUENGOER T.; MARSAIS F. QUEGUINER G., J. OF ORGANOMETALL. CHEM., 1981, 215, 139-150
作者:CUENGOER T.、 MARSAIS F. QUEGUINER G.
DOI:——
日期:——
5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS
申请人:Takeda Pharmaceutical Company Limited
公开号:EP2190822B1
公开(公告)日:2014-12-31
TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
申请人:Gilead Sciences, Inc.
公开号:US20210171500A1
公开(公告)日:2021-06-10
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
[EN] 5-MEMBERED HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE À 5 CHAÎNONS
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2009041705A2
公开(公告)日:2009-04-02
The present invention provides compounds represented by the formula (I): The present compounds have a superior acid secretion inhabitory effect, and show a antiulcer activity.